Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III Study

Clinical Therapeutics

Volumn 39, Issue 10, 2017, Pages 2049-2060

  Hong, Soon Jun ^a   Jeong, Han Saem ^a   Han, Seung Hwan ^b   Chang, Ki Yuk ^c   Hong, Bum Kee ^d   Lee, Bong Ki ^e   Chae, Shung Chull ^f   Kim, Woo Shik ^g   Park, Chang Gyu ^h   Heo, Jung Ho ⁱ   Lee, Seung Uk ^j   Kim, Young Dae ^k   Kim, Kee Sik ^l   Choi, Jung Hyun ^m   Kang, Hyun Jae ⁿ   Kim, Jae Joong ^o   Kang, Seok Min ^p   Choi, Young Jin ^q   Shin, Joon Han ^r   Chun, Kook Jin ^s   Shin, Dong Gu ^t   Park, Seong Hoon ^u   Kwan, Jun ^v   Choi, Yu Jeong ^w   Jeong, Myung Ho ^x   Chae, Jei Keon ^y   Kim, Dong Woon ^z   Cho, Jung Rae ^aa   Han, Kyoo Rok ^ab   Won, Kyung Heon ^ac   Park, Sang Ho ^ad   Lee, Sang Kon ^ae   Kim, Sang Hoon ^af   Jung, Jina ^ag   Kim, Cheol Ho ^ah   more..

^a College of Medicine   (South Korea)

^b Gachon University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Kangwon National University   (South Korea)

^f Kyungpook National University Hospital   (South Korea)

^g Kyung Hee University College of Medicine   (South Korea)

^h Korea University College of Medicine   (South Korea)

ⁱ Kosin University   (South Korea)

^j Gwangju Christian Hospital   (South Korea)

^k Dong A University College of Medicine   (South Korea)

^l Catholic University of Daegu   (South Korea)

^m Pusan National University School of Medicine   (South Korea)

ⁿ Seoul National University Hospital   (South Korea)

^o University of Ulsan   (South Korea)

^p Yonsei University   (South Korea)

^q Sejong Hospital   (South Korea)

^r Ajou University School of Medicine   (South Korea)

^s Pusan National University Yangsan Hospital   (South Korea)

^t Young Nam University Hospital   (South Korea)

^u Ewha Womans University   (South Korea)

^v Inha University Hospital   (South Korea)

^w Eulji University   (South Korea)

^x Chonnam National University Medical School   (South Korea)

^y Chonbuk National University Medical School   (South Korea)

^z Chungbuk National University Hospital   (South Korea)

^aa Kangnam Sacred Heart Hospital   (South Korea)

^ab Kangdong Sacred Heart Hospital   (South Korea)

^ac Seoul Medical center ^*  (South Korea)

^ad Soonchunhyang University   (South Korea)

^ae University of Ulsan College of Medicine   (South Korea)

^af CHA bundang medical center   (South Korea)

^ag Hanmi Pharmaceutical Co Ltd   (South Korea)

^ah Seoul National University Bundang Hospital   (South Korea)

more..

Author keywords

amlodipine; chlorthalidone; hypertension; losartan; single pill combination

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS CHLORTHALIDONE PLUS LOSARTAN POTASSIUM; AMLODIPINE PLUS LOSARTAN POTASSIUM; ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; CREATININE; LOSARTAN POTASSIUM; UNCLASSIFIED DRUG; URIC ACID; LOSARTAN;

ABDOMINAL DISTENSION; ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; ATRIAL FIBRILLATION; BLOOD PRESSURE MONITORING; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC DISCOMFORT; ESOPHAGITIS; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INSOMNIA; KIDNEY DISEASE; KOREAN (PEOPLE); LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; PARESTHESIA; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; SITTING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; URINARY TRACT DISEASE; VASCULAR DISEASE; VITAL SIGN; AGED; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHLORTHALIDONE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85029596842     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.08.013     Document Type: Article

References (32)

1. Stokes, J. 3rd, Kannel, W.B., Wolf, P.A., et al. Blood pressure as a risk factor for cardiovascular disease: the Framingham Study-30 years of follow-up. Hypertension 13 (1989), I13–I18.
2. Staessen, J.A., Fagard, R., Thijs, L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 (1997), 757–764.
3. Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34 (2013), 2159–2219.
4. Lewington, S., Clarke, R., Qizilbash, N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
5. Kearney, P.M., Whelton, M., Reynolds, K., et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 22 (2004), 11–19.
6. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265 (1991), 3255–3264.
7. Rodgers, A., Lawes, C., MacMahon, S., Reducing the global burden of blood pressure-related cardiovascular disease. J Hypertens Suppl 18 (2000), S3–S6.
8. James, P.A., Oparil, S., Carter, B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
9. Gupta, A.K., Arshad, S., Poulter, N.R., Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55 (2010), 399–407.
10. Claxton, A.J., Cramer, J., Pierce, C., A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001), 1296–1310.
11. McManus, R.J., Caulfield, M., Williams, B., National Institute for H, Clinical E. NICE hypertension guideline 2011: evidence based evolution. BMJ, 344, 2012, e181.
12. Gavras, H.P., Salerno, C.M., The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 18 (1996), 1058–1067 discussion 1057.
13. Levine, C.B., Fahrbach, K.R., Frame, D., et al. Effect of amlodipine on systolic blood pressure. Clin Ther 25 (2003), 35–57.
14. Carter, B.L., Ernst, M.E., Cohen, J.D., Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 43 (2004), 4–9.
15. Ernst, M.E., Carter, B.L., Zheng, S., Grimm, R.H. Jr, Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens 23 (2010), 440–446.
16. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 283 (2000), 1967–1975.
17. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 82 (1990), 1616–1628.
18. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 242 (1979), 2562–2571.
19. Kreutz, R., Ammentorp, B., Laeis, P., de la Sierra, A., Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. J Clin Hypertens (Greenwich) 16 (2014), 729–740.
20. Clark, L.T., Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J 121 (1991), 664–669.
21. Neutel, J.M., Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens 12 (1999), 73S–79S.
22. Wald, D.S., Law, M., Morris, J.K., et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122 (2009), 290–300.
23. Bronsert, M.R., Henderson, W.G., Valuck, R., et al. Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. J Am Board Fam Med 26 (2013), 529–538.
24. Cicero, A.F., Gerocarni, B., Rosticci, M., Borghi, C., Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 34 (2012), 113–117.
25. Ferri, C., Croce, G., Desideri, G., Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Adv Ther 25 (2008), 300–320.
26. McDowell, S.E., Coleman, J.J., Ferner, R.E., Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332 (2006), 1177–1181.
27. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002), 995–1003.
28. Sung, J., Jeong, J.O., Kwon, S.U., et al. Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy. Korean Circ J 46 (2016), 222–228.
29. Makani, H., Bangalore, S., Romero, J., et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 124 (2011), 128–135.
30. Dorsch, M.P., Gillespie, B.W., Erickson, S.R., et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 57 (2011), 689–694.
31. Calhoun, D.A., Lacourciere, Y., Chiang, Y.T., Glazer, R.D., Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 54 (2009), 32–39.
32. Julius, S., Kjeldsen, S.E., Weber, M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004), 2022–2031.